DOJ Fraud Section Closes Research Misconduct Inquiry Against Cassava Sciences
SAVA sits 86% above its 52-week low of $1.15 on light trading volume (0.3× avg).
Summary
Cassava Sciences announced the closure of the U.S. Department of Justice Fraud Section's inquiry into allegations of research misconduct, removing a major legal and reputational risk.
Key Events · Legal and Risk Events · SAVA
-
DOJ Inquiry Closed
The U.S. Department of Justice Fraud Section has formally closed its inquiry into Cassava Sciences regarding allegations of research misconduct.
-
Prior Indictment Dismissed
The inquiry was related to an indictment in United States v. Wang, which was previously dismissed with prejudice by the DOJ on October 23, 2025.
-
SEC Settlement Previously Reached
This resolution follows a settlement with the U.S. Securities and Exchange Commission (SEC) in September 2024 regarding negligence-based disclosure charges, concluding all major investigations into the company.
Analysis · SAVA · Life Sciences
The closure of the U.S. Department of Justice Fraud Section's inquiry into allegations of research misconduct removes a significant legal and reputational overhang for Cassava Sciences. For a biotechnology company, such investigations can severely impact investor confidence, partnership opportunities, and the progression of clinical trials. This definitive resolution, following the prior dismissal of an indictment and settlement with the SEC, substantially de-risks the company's profile and allows management to fully focus on its core drug development activities, particularly for TSC-related epilepsy.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SAVA was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.9M. The 52-week trading range was $1.15 to $4.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.